key: cord-0780883-fgldyrv2
authors: Bleve, E.; Venditti, V.; Lenzi, A.; Morano, S.; Filardi, T.
title: COVID-19 vaccine and autoimmune diabetes in adults: report of two cases
date: 2022-03-29
journal: J Endocrinol Invest
DOI: 10.1007/s40618-022-01796-5
sha: d26cd4e83731a85fd2b8cd3d1e510f747b278d7d
doc_id: 780883
cord_uid: fgldyrv2

nan

chest or abdominal pain or any signs or symptoms suggesting infection, such as fever, chills, cough, dyspnea, urgency, or hesitancy. SARS-Cov-2 mRNA testing revealed a negative result. Circulating volume was replaced with 0.9% NaCl solution and the hyperglycemic state was corrected with rapid insulin administration. Since she refused hospital admission, she was discharged on March 27th, 2021 with a basal-bolus insulin therapy regimen. Glycosylated hemoglobin (HbA1c) was 90 mmol/mol (10.38%) when dosed for the first time on April 15th, 2021. Elevated levels of anti-glutamic acid decarboxylase antibodies (Anti-GAD), anti-tyrosine phosphatase antibodies (Anti-IA2), and antitransglutaminase IgA antibody (Anti-TransGlut IgA) were found.

The second patient was a 61-year-old Caucasian woman complaining of polyuria, polydipsia, and asthenia since the administration of the second dose of Comirnaty BioNTech vaccine on June 4th, 2021. A few days later, the patient developed severe dyspnea, nausea, and abdominal pain, and she was admitted to the Emergency Room on June 30th, 2021. She reported medical history of acquired hypothyroidism. At the Emergency Department, physical examination suggested an acute abdomen. SARS-Cov-2 mRNA testing revealed a negative result. Blood analysis showed elevated levels of FPG (640 mg/dl) and metabolic acidosis. Physiologic 0.9 NaCl solution was infused, and the hyperglycemic state was corrected with rapid insulin administration. On June 6th, 2021, the patient was discharged with basal-bolus insulin therapy regimen. The patient was first evaluated in the outpatient clinics of Endocrinology and Diabetes on July 9th, 2021. HbA1c was 102 mmol/mol (11.5%) when dosed for the first time on July 5th, 2021, and elevated levels of anti-GAD and anti-thyroid peroxidase antibodies (Anti-TPO) were found. One month after first evaluation (and two months after vaccine administration) the patient developed cutaneous maculopapular erythematous lesions associated with edema to arms and legs. Skin biopsy showed lymphocytic invasion of dermis, mostly peri vasal; corticosteroid therapy was initiated with resolution.

COVID-19 vaccines are the most effective tool against severe disease and death so far, and they have largely demonstrated to have a good safety profile. Although causality cannot be proven and the pathophysiological mechanisms underlying the putative link between COVID-19 vaccine administration and decompensated diabetes are still unclear, it can be speculated that COVID-19 vaccine may trigger immunological response that may lead to an overproduction of different cytokines, like the SARS-CoV-2 infection, worsening an already subclinical altered glycemic state [5] . However, it has been observed that immune response triggered by COVID-19 vaccines leads to the production of different pro-inflammatory cytokines, which play a pivotal role in the pathogenesis of insulin-resistance and pancreatic beta-cell autoimmune damage [6] . The increased circulating levels of these pro-inflammatory cytokines observed after vaccine might overlap an already imposed autoimmune process, exacerbating pancreatic beta-cell inflammation and contributing to clinically manifest diabetes. Further studies are needed to deepen the understanding of the pathophysiological basis of this putative relationship.

COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?

New-onset diabetes in Covid-19

COVID-19, hyperglycemia, and new-onset diabetes

New onset diabetes, type 1 diabetes and COVID-19

Exacerbation of hyperglycemia in patients with type 2 diabetes after vaccination for COVID19: report of three cases

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Acknowledgements This research did not receive any specific grant